Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Castagna

Showing results (171-180 of 203) with videos related to

Pageof 21
Sort By:
Blood Advances|December 3, 2021
Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristicsMehdi Hamadani, Maud Ngoya, Anna Sureda, et al.
Cancer|October 24, 2018
Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working PartyAli Bazarbachi, Ariane Boumendil, Hervé Finel, et al.
Transplantation and Cellular Therapy|July 13, 2022
Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationAnnalisa Ruggeri, Jacques-Emmanuel Galimard, Myriam Labopin, et al.
Bone Marrow Transplantation|June 25, 2022
Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMTRaynier Devillier, Jacques-Emmanuel Galimard, Myriam Labopin, et al.
Transplantation and Cellular Therapy|September 20, 2021
Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow TransplantationFiroozeh Sahebi, Dirk-Jan Eikema, Linda Koster, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 30, 2013
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor RegistryRoberto Passera, Simona Pollichieni, Lucia Brunello, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2020
Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTRGiancarlo Fatobene, Vanderson Rocha, Andrew St Martin, et al.
British Journal of Haematology|September 10, 2019
Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT studyAli Bazarbachi, Ariane Boumendil, Hervé Finel, et al.
Bone Marrow Transplantation|January 14, 2018
Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMTSimone Cesaro, Roberto Crocchiolo, Gloria Tridello, et al.
Blood Advances|February 7, 2019
PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCLPeter Dreger, Anna Sureda, Kwang Woo Ahn, et al.
Pageof 21

Showing results (171-180 of 203) with videos related to

Sort By:
Pageof 21
Blood Advances|December 3, 2021
Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristicsMehdi Hamadani, Maud Ngoya, Anna Sureda, et al.
Cancer|October 24, 2018
Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working PartyAli Bazarbachi, Ariane Boumendil, Hervé Finel, et al.
Transplantation and Cellular Therapy|July 13, 2022
Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationAnnalisa Ruggeri, Jacques-Emmanuel Galimard, Myriam Labopin, et al.
Bone Marrow Transplantation|June 25, 2022
Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMTRaynier Devillier, Jacques-Emmanuel Galimard, Myriam Labopin, et al.
Transplantation and Cellular Therapy|September 20, 2021
Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow TransplantationFiroozeh Sahebi, Dirk-Jan Eikema, Linda Koster, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 30, 2013
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor RegistryRoberto Passera, Simona Pollichieni, Lucia Brunello, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2020
Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTRGiancarlo Fatobene, Vanderson Rocha, Andrew St Martin, et al.
British Journal of Haematology|September 10, 2019
Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT studyAli Bazarbachi, Ariane Boumendil, Hervé Finel, et al.
Bone Marrow Transplantation|January 14, 2018
Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMTSimone Cesaro, Roberto Crocchiolo, Gloria Tridello, et al.
Blood Advances|February 7, 2019
PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCLPeter Dreger, Anna Sureda, Kwang Woo Ahn, et al.
Pageof 21